Michael J DeVito

Dr. Michael J DeVito

orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2001 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
TZTong Zhou
Tong Zhou
DRDavid G. Ross
David G. Ross
MDMichael J DeVito
Michael J DeVito
KCKevin M. Crofton
Kevin M. Crofton
Polybrominated diphenyl ethers (PBDEs), used as flame retardants, are ubiquitous environmental contaminants. PBDEs act as endocrine disruptors via alterations in thyroid hormone homeostasis. We examined thyroid hormone concentrations and hepatic enzyme activity in weanling rats exposed to three commercial PBDE mixtures: DE-71, DE-79, and DE-83R. Female Long-Evans rats, 28 days old, were orally administered various doses of DE-71, DE-79, or DE-83R for 4 days. Serum and liver samples were collected 24 h after the last dose and analyzed for serum total thyroxine (T4), triiodothyronine (T3), thyroid-stimulating hormone (TSH), hepatic microsomal ethoxy- and pentoxy-resorufin-O-deethylase (EROD and PROD), and uridinediphosphate-glucuronosyltransferase (UDPGT) activities. The PBDE-treated groups did not exhibit significant changes in body weight; however, increased liver weights, as well as 10- to 20-fold induction in EROD and 30- to 40-fold induction in PROD were found in the DE-71– and DE-79–treated animals. DE-71 and DE-79 caused dose-dependent depletion of T4, accompanied by up to 3- to 4-fold induction in UDPGT activities. Serum total T4 was decreased a maximum of 80% for DE-71 and 70% for DE-79 in the highest dose, with benchmark doses (BMDs) of approximately 12.74 mg/kg/day for DE-71 and 9.25 mg/kg/day for DE-79. Dose-related effects in serum T3 levels were less apparent, with maximal reductions of 25–30% at the highest dose for both DE-71 and DE-79. The two mixtures showed no effect on serum TSH levels. Benchmark dose analysis revealed that the two mixtures were comparable in altering thyroid hormone levels and hepatic enzyme activity. DE-83R was not effective in altering any of the measured parameters. The present study suggests that short-term exposure to some commercial PBDE mixtures interferes with the thyroid hormone system via upregulation of UDPGTs.

19 August 2013 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
RTRussell S. Thomas
Russell S. Thomas
MPMartin A. Philbert
Martin A. Philbert
SAScott S. Auerbach
Scott S. Auerbach
BWBarbara A. Wetmore
Barbara A. Wetmore
MDMichael J DeVito
Michael J DeVito
ANAndy Nong
Andy Nong
Based on existing data and previous work, a series of studies is proposed as a basis toward a pragmatic early step in transforming toxicity testing. These studies were assembled into a data-driven framework that invokes successive tiers of testing with margin of exposure (MOE) as the primary metric. The first tier of the framework integrates data from high-throughput in vitro assays, in vitro-to-in vivo extrapolation (IVIVE) pharmacokinetic modeling, and exposure modeling. The in vitro assays are used to separate chemicals based on their relative selectivity in interacting with biological targets and identify the concentration at which these interactions occur. The IVIVE modeling converts in vitro concentrations into external dose for calculation of the point of departure (POD) and comparisons to human exposure estimates to yield a MOE. The second tier involves short-term in vivo studies, expanded pharmacokinetic evaluations, and refined human exposure estimates. The results from the second tier studies provide more accurate estimates of the POD and the MOE. The third tier contains the traditional animal studies currently used to assess chemical safety. In each tier, the POD for selective chemicals is based primarily on endpoints associated with a proposed mode of action, whereas the POD for nonselective chemicals is based on potential biological perturbation. Based on the MOE, a significant percentage of chemicals evaluated in the first 2 tiers could be eliminated from further testing. The framework provides a risk-based and animal-sparing approach to evaluate chemical safety, drawing broadly from previous experience but incorporating technological advances to increase efficiency.

14 March 2013 in Toxicological Sciences
Verified
Journal Article
Open access
PDF file
MBMartin van Den Berg
Martin van Den Berg
MDMichael S. Denison
Michael S. Denison
LBLinda S. Birnbaum
Linda S. Birnbaum
MDMichael J DeVito
Michael J DeVito
HFHeidelore Fiedler
Heidelore Fiedler
RPRichard E. Peterson
Richard E. Peterson
In 2011, a joint World Health Organization (WHO) and United Nations Environment Programme (UNEP) expert consultation took place, during which the possible inclusion of brominated analogues of the dioxin-like compounds in the WHO Toxicity Equivalency Factor (TEF) scheme was evaluated. The expert panel concluded that polybrominated dibenzo-p-dioxins (PBDDs), dibenzofurans (PBDFs), and some dioxin-like biphenyls (dl-PBBs) may contribute significantly in daily human background exposure to the total dioxin toxic equivalencies (TEQs). These compounds are also commonly found in the aquatic environment. Available data for fish toxicity were evaluated for possible inclusion in the WHO-UNEP TEF scheme (van den Berg et al., 1998). Because of the limited database, it was decided not to derive specific WHO-UNEP TEFs for fish, but for ecotoxicological risk assessment, the use of specific relative effect potencies (REPs) from fish embryo assays is recommended. Based on the limited mammalian REP database for these brominated compounds, it was concluded that sufficient differentiation from the present TEF values of the chlorinated analogues (van den Berg et al., 2006) was not possible. However, the REPs for PBDDs, PBDFs, and non-ortho dl-PBBs in mammals closely follow those of the chlorinated analogues, at least within one order of magnitude. Therefore, the use of similar interim TEF values for brominated and chlorinated congeners for human risk assessment is recommended, pending more detailed information in the future.

1 September 2007 in Environmental Toxicology and Pharmacology
Verified
Journal Article
Closed access
KCKevin M. Crofton
Kevin M. Crofton
KPKatie B. Paul
Katie B. Paul
MDMichael J DeVito
Michael J DeVito
JHJoan M. Hedge
Joan M. Hedge

1 November 2005 in Environmental Health Perspectives
Verified
Journal Article
Open access
KCKevin M. Crofton
Kevin M. Crofton
ECElena S. Craft
Elena S. Craft
JHJoan M. Hedge
Joan M. Hedge
CGChris Gennings
Chris Gennings
JSJane E. Simmons
Jane E. Simmons
MDMichael J DeVito
Michael J DeVito
Endocrine disruption from environmental contaminants has been linked to a broad spectrum of adverse outcomes. One concern about endocrine-disrupting xenobiotics is the potential for additive or synergistic (i.e., greater-than-additive) effects of mixtures. ...

1 February 2008 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
VRVicki M. Richardson
Vicki M. Richardson
DSDaniele F. Staskal
Daniele F. Staskal
DRDavid G. Ross
David G. Ross
JDJanet J. Diliberto
Janet J. Diliberto
MDMichael J DeVito
Michael J DeVito
LBLinda S. Birnbaum
Linda S. Birnbaum